{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 23 of 92', 'CR845-CLIN3102', 'CR845-CLIN2101 (Part A) evaluated the safety, pharmacokinetics, and efficacy of', 'repeated IV doses of CR845 compared to placebo over an 8-week treatment period in', '174 hemodialysis patients. This study is the longest treatment period evaluated to date in', 'hemodialysis patients and no clinically important or significant safety findings related to', 'CR845 were noted. As expected with patients on hemodialysis, a significant number of', 'the reported serious adverse events (SAEs) were considered not treatment-related, but', 'related to the disease and/or comorbid conditions. There were 31 (17.8%) of 174 patients', 'randomized and treated in the study who had treatment-emergent SAEs. Of the 31 SAE', 'reports, 4 (9%) occurred in 45 placebo-treated patients and 27 (21%) in', '129 CR845-treated patients. Only 1 SAE of mental status changes (moderate in severity)', 'in a patient who received CR845 1.5 mcg/kg IV was considered by the Investigator to be', \"probably related to study drug. However, based on the Sponsor's medical review, an\", 'alternate etiology of urgent/emergent hypertension offers a more plausible explanation', 'for the acute change in mental status. There were 4 patient deaths (2.3%) in the study, all', 'of which were considered not related to the study drug.', 'In patients with normal renal function, CR845 can cause free-water diuresis (aquaresis)', 'and increased serum sodium. However, as would be expected in patients undergoing', 'dialysis in whom there are few functioning nephrons, there was no evidence of aquaresis', 'or significant increases in serum sodium concentrations. There were no adverse trends in', 'clinical chemistry or hematology values (drawn pre-dialysis), including, no apparent', 'differences between the placebo and CR845 groups in serum sodium. There were no', 'discernable differences between treatment groups in vital sign results. Of particular note,', 'among patients receiving CR845, there was no apparent reduction in blood pressure or', 'respiratory rate following dosing.', \"Adverse event summary tables can be found in the Investigator's Brochure, with further\", 'details of the safety profile of CR845.', '4.2.3', 'Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus', 'The efficacy of CR845 in uremic pruritus was evaluated in two Phase 2, randomized,', 'double-blind, placebo-controlled studies (CR845-CLIN2005 [Part B and', 'CR845-CLIN2101 [Part A]).', 'CR845-CLIN2005 (Part B) included 65 hemodialysis patients with moderate-to-severe', 'uremic pruritus who received either IV CR845 1.0 mcg/kg (n=33) or placebo (n=32)', '3 times per week for 2 weeks, after each hemodialysis session. CR845 significantly', 'decreased itching intensity compared with placebo (p=0.016), as measured by a visual', 'analog scale (VAS) and significantly improved quality of life related to itching', \"(Skindex-10 Scale) (see Investigator's Brochure for details). Furthermore,\", 'CR845-treated patients exhibited statistically significant reductions in both daytime', '(p=0.03) and nighttime (p=0.007) worst itching scores compared with placebo, and the', 'reduction in itching intensity scores was similar on dialysis and nondialysis days. The', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 25 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 24 of 92', 'CR845-CLIN3102', 'mean change from baseline VAS curves over time showed numerical separation between', 'the treatment groups within the first week of treatment.', 'CR845-CLIN2101 (Part A) evaluated the safety, pharmacokinetics, and efficacy of', 'repeated IV doses of CR845 compared to placebo over an 8-week treatment period in', '174 hemodialysis patients experiencing moderate-to-severe uremic pruritus daily or', 'near-daily for 4.4 years on average. The study was conducted at 33 dialysis centers and', 'assessed the effect of 3 doses of CR845 (ie, 0.5 mcg/kg, n=44; 1 mcg/kg, n=41 and', '1.5 mcg/kg, n=44) or placebo (n=45) administered at the end of each dialysis session', '(ie, 3 times/week). The primary efficacy endpoint for Study CR845-CLIN2101 (Part A)', 'was based on itch intensity measurement and defined as the change from a 1-week', 'baseline recorded prior to the start of study drug to the last week of the 8-week treatment', 'period with respect to the weekly mean of the daily 24-hour Worst Itching Intensity', 'numerical rating scale (NRS) score. The least squares (LS) mean (=standard error [SE])', 'treatment group difference from placebo at Week 8 across all CR845 doses', 'was - -1.3 (=0.41) (95% confidence interval [CI]: -2.1 to -0.5) (p=0.002) with an average', 'NRS score reduction from baseline of -3.2 (=0.22) (LS mean SE) and 95% CI ranging', 'from -3.7 to -2.8. Examination of the individual CR845 dose group results for the Full', 'Analysis Population indicates that a substantial improvement over placebo was observed', 'with all 3 doses. These differences from placebo were statistically significant for the', 'lower dose group of 0.5 mcg/kg (p<0.001) and the 1.5 mcg/kg group (p=0.019), with an', 'effect size estimated as 0.82, 0.39, and 0.62 for the 0.5, 1.0, and 1.5 mcg/kg doses,', 'respectively. Average reduction from baseline (LS mean SE) ranged from -2.8 (=0.38)', 'in the 1.0 mcg/kg dose group (95% CI ranging from -3.5 to -2.0) to -3.8 (=0.38) in the', '0.5 mcg/kg dose group (95% CI ranging from -4.5 to -3.1).', '4.2.4', 'Pharmacokinetics in Hemodialysis Patients', 'CR845 is eliminated primarily through the kidney and no major metabolites have been', 'identified in humans. Consequently, total body clearance of CR845 in patients with', 'severe renal impairment is reduced relative to healthy, matched, control patients', '(CR845-CLIN1005) such that plasma levels of CR845 remain relatively constant until', 'cleared during dialysis in hemodialysis patients (CR845-CLIN1003 and', 'CR845-CLIN2005 [Part A]). Half-life ranges between 26 and 34 hours in hemodialysis', 'patients compared to a typical range of 2 to 3 hours in patients with normal renal', 'function. Thus, lower doses of CR845 can be administered at a less frequent interval in', 'hemodialysis patients to achieve the same or higher overall exposure compared to', 'individuals with normal renal function. Based on this pharmacokinetic profile, CR845', 'does not need to be administered more than 3 times a week after each hemodialysis', 'session, which is convenient for this patient population and ensures treatment compliance', 'in a population already burdened with complex medication schedules.', 'The pharmacokinetic profile of repeat-dose CR845 was studied in 24 hemodialysis', 'patients who received doses of 0.5, 1.0, or 2.5 mcg/kg 3 times per week for 1 week', '(CR845-CLIN2005 Part A]). In this study, there were dose-proportional increases in', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 26 of 95']\n\n###\n\n", "completion": "END"}